Red Blood Cell Exchange Transfusion as a Novel Treatment for GLUT1 Deficiency Syndrome

Glucose Transporter Type 1 Deficiency Syndrome Clinical Trial

Official title:

Red Blood Cell Exchange Transfusion as a Novel Treatment for GLUT1 Deficiency Syndrome

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04137692
• Other study ID #: UTSW 122014-010
• Status: Active, not recruiting
• Phase: N/A
• Start date: March 9, 2020
• Est. completion date: October 2028

Study information

• Verified date: November 2023
• Source: University of Texas Southwestern Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This proposal is an investigator-initiated, single-site proof of concept trial. Five patients will undergo isovolemic hemodilution-red cell exchange (IHD- RBCx) with up to 10 units of red cell antigens (Rh group, Kell, Duffy, Kidd blood group antigens) matched normal donor red cells to replace a target of 70% of the patient's red cells with donor red cells. The procedure will be performed as an outpatient according to protocols established for sickle cell anemia patients. One of the investigators is an expert on RBCx and will oversee the transfusion. Subjects will be assessed before and after transfusion, and at two months post transfusion. Outcome measures include neurological exam, electroencephalography (EEG), neuropsychological testing, and biochemical assays.

Description:

As the transporter responsible for basal levels of glucose flux, Glucose transporter 1 (GLUT1) is expressed at low levels in most tissues. In contrast, GLUT1 is very highly expressed on human erythrocytes. Human erythrocytes possess up to 5x105 copies of GLUT1 in their membranes representing almost 5% of total membrane protein. This allows erythrocytes to catalyze glucose transfer at rates three orders of magnitude greater than their capacity to utilize it. It has been proposed that human erythrocytes function in glucose storage, especially when the serum carrying capacity for glucose becomes limiting. If this hypothesis could be validated experimentally, it would be of fundamental importance to the understanding of human physiology.

This proposal also has the potential to uncover a novel therapeutic option for patients with Glucose Transporter Type 1 Deficiency (G1D). Currently, the only treatment for G1D is the ketogenic diet. While the ketogenic diet improves seizures in a fraction of patients, its effects on neurodevelopment and long-term health are poor, so better treatment options for G1D are needed. Because of the hypoglycorrachia (i.e. low cerebrospinal fluid glucose) of G1D patients, the endothelial cells of the blood-brain barrier microvessels have long been assumed to be the primary site of disease pathogenesis. However, most G1D patients also have deficits in GLUT1 levels and glucose uptake in their erythrocytes and a potential contribution of this compartment to disease pathogenesis is likely. GLUT1 deficient mice are not amenable to test the hypothesis because they do not fully recapitulate the clinical presentation of G1D patients and because they exhibit metabolic adaption to G1D. Red blood cell exchange (RBCx) is a safe and cost effective treatment to prevent strokes and vascular abnormalities in patients with sickle cell anemia. RBCx has the potential to dramatically alter the treatment of G1D patients.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 5
• Est. completion date: October 2028
• Est. primary completion date: October 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years to 64 Years

Eligibility

Inclusion Criteria:

• Male or Female

• Age 16 years to 64 years old.

• Diagnosed with genetically-confirmed glucose transporter type 1 disorder

• Patients not currently receiving dietary therapy, including ketogenic diet or other dietary therapy, due to failure of these diets to achieve seizure remission or due to patient preference, including compliance or tolerance issues. Patients currently on Modified Atkins Diet (MAD) and / or taking Medium Chain Triglyceride (MCT) oil are allowed.

Exclusion Criteria:

• Currently on the ketogenic diet or taking triheptanoin (C7) oil

• No genetic confirmation of G1D diagnosis

• Unable to return for follow up visits

• Weak peripheral veins, such that IV placement is contraindicated (required for transfusion)

• Serious chronic medical conditions, such as congestive heart failure, renal failure, liver failure, or any other medical conditions that preclude large volume transfusions.

• Patients currently pregnant or breast-feeding are excluded from participating in this research. Patients who plan on getting pregnant during this research or who are unwilling to use birth control, including abstinence, during the course of this research are also excluded due to safety concerns for the fetus.

Related Conditions & MeSH terms

• Glucose Transporter Type 1 Deficiency Syndrome
• GLUT1DS1
• Syndrome

Intervention

Other:
• Red Blood Cell Transfusion
The procedure will be performed as an outpatient according to protocols established for sickle cell anemia patients. Two IVs are placed for the purposes of transfusion, one for draw and one for return. Patients will undergo isovolemic hemodilution-red cell exchange (IHD- RBCx) with up to 10 units of red cell antigens (Rh group, Kell, Duffy, Kidd blood group antigens) matched normal donor red cells to replace a target of 70% of the patient's red cells with donor red cells.Total time of procedure: approximately 150 minutes.

Locations

Country	Name	City	State
United States	UT Southwestern	Dallas	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Juan Pascual

Country where clinical trial is conducted

United States, 

References & Publications (1)

Lee EE, Ma J, Sacharidou A, Mi W, Salato VK, Nguyen N, Jiang Y, Pascual JM, North PE, Shaul PW, Mettlen M, Wang RC. A Protein Kinase C Phosphorylation Motif in GLUT1 Affects Glucose Transport and is Mutated in GLUT1 Deficiency Syndrome. Mol Cell. 2015 Jun 4;58(5):845-53. doi: 10.1016/j.molcel.2015.04.015. Epub 2015 May 14. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in electroencephalogram (EEG)	Change in number of seizures recorded	Baseline, during transfusion, and 60 days after transfusion
Secondary	Change in neuropsychological receptive language test battery	Change in standard scores obtained from the Peabody Picture Vocabulary Test.	Baseline, immediately after transfusion, and 60 days after transfusion
Secondary	Change in neuropsychological expressive language test battery	Change in standard scores obtained from the Expressive Vocabulary Test.	Baseline, immediately after transfusion, and 60 days after transfusion
Secondary	Change in neuropsychological attention scores	Change in T-scores obtained on the Connors Continuous Performance Test. Minimum T score is less than 30. Maximum T score is 90. Higher T scores for Hit Reaction Time domain indicate slower reaction time while lower scores indicate faster reaction time. For all other domains (detectability, omissions, commissions, perseverations), higher T scores indicated elevated performance while lower T scores indicate lower performance.	Baseline, immediately after transfusion, and 60 days after transfusion
Secondary	Changes in biochemical assay	Number of participants with erythrocyte Glut1 levels that have increased by over 40% from baseline.	Baseline, immediately after transfusion, and 60 days after transfusion
Secondary	Change in General Medical & Neurological Examination	Change in score of standardized clinical physical exam, which has 12 domains scored either normal or abnormal. Minimum total score is 0. Maximum total score is 76. Lower scores are considered more abnormal. Higher scores indicate a more normal exam and and better outcomes than lower scores.	Baseline and 60 days after transfusion